Figure 3.

Potential benefits of epigenetic combination therapy in the clinical management of cancer. Cancer monotherapies are associated with a variety of adverse events in the clinical management of patients, including cancer-related fatigue, treatment-related pneumonia, nausea and vomiting, hemorrhage, liver impairment, diarrhea and constipation, alopecia, skin rashes, hypertension, and giddiness. In addition, cancer monotherapies are mostly prone to multidrug resistance, recurrence, and metastasis, all of which have a negative impact on the quality of life and clinical outcomes of patients. Epigenetic drugs have shown great potential in cancer treatment. Epigenetic combination therapy not only enhances antitumor effects and reduces resistance to other anticancer drugs but also lowers the incidence of treatment-related adverse events. In addition, epigenetic combination therapy may improve the clinical outcome and prognosis of patients to some extent. In conclusion, epigenetic combination therapy may be a promising strategy for cancer treatment.